Tests detecting 4 SARS-CoV-2 coronavirus genes
genXone’s molecular diagnostics lab now offers COVID-19 testing identifying four coronavirus genes, with improved sensitivity, internal controls, and reduced false positives.
genxone.euCrawled Nov 20, 2026
genXone’s molecular diagnostics lab now offers COVID-19 testing identifying four coronavirus genes, with improved sensitivity, internal controls, and reduced false positives.
The company provides a containerized, mobile lab for safe molecular testing, including coronavirus diagnostics.
genXone highlights its presence in science and business through nanopore sequencing applications.
genXone collaborates with international centers to create affordable, scalable solutions for genetic disease diagnostics.
The sample collection point on Zacisze Street in Poznań processed 125 COVID-19 swabs in its first week of operation.
The company opened a sample collection point where patients referred by the National Health Fund and those who purchase a COVID-19 test after scheduling an appointment can receive swabs. The point operates near the city hospital in a blue pavilion on Zacisze Street in Poznań.
genXone’s November focus is on growth: the company expanded its team by six employees and is working to double sample analysis capacity. It also advances the Nanobiome project, with Dr. Grzegorz Nowicki discussing its scientific aspects at an upcoming conference.
The sample collection point in Poznań’s city center performed over 750 COVID-19 swabs in October alone, with over 600 for National Health Fund patients. It operates with high safety standards, including personal protective equipment for staff and patients.
genXone is launching a mobile laboratory in partnership with NewLab Systems.
genXone’s Research and Development Laboratory began preparing to sequence SARS-CoV-2 genomes from positive patient samples using Nanopore technology, enabling real-time tracking of infection clusters.
genXone S.A.’s Molecular Diagnostics Laboratory is listed as a regional COVID-19 testing facility.
genXone S.A. equipped its laboratory to perform SARS-CoV-2 diagnostic tests using RT-PCR, including safety protocols, personal protective equipment, and secure transport materials.
The company reduced diagnostic test prices due to increased demand for molecular research, enabling economies of scale. It also contributed additional SARS-CoV-2 genome records to GISAID, including a confirmed case of the British variant.
The company lowered diagnostic test prices due to higher demand for molecular research, achieving cost efficiencies. It added coronavirus genome sequences to the GISAID database, including a second confirmed case of the British variant.
genXone’s strategy relies on innovative nanopore sequencing solutions. The page outlines its goals and main projects.
genXone develops solutions for medicine, science, and business using Oxford Nanopore Technologies’ nanopore sequencing, launched in 2016.
The company plans to release the first version of the Nanobiome test in autumn 2021.
The swab collection point in Tarnów Podgórny operates 24/7 starting Monday, February 7.
genXone offers next-generation sequencing, diagnostic testing, and medical device efficacy assessments.
genXone signed a cooperation agreement with Diagnostyka to conduct RT-PCR tests worth 5.5 million złoty over two years.
The company’s organizational structure includes genXone SA Molecular Diagnostics Laboratory, which operates a Diagnostic Laboratory unit.
genXone’s store outlines rules for purchasing molecular, genetic, and immunological diagnostic tests.